EGFR and lung adenocarcinoma: The most significant support to this first evidence came from the integrative multi-omics analysis by Xu Z and colleagues, who investigated the EGFR genes in terms of CpGs methylation (49 CpG sites), somatic mutations, copy number variations (CNVs), transcriptional and protein expression level fluctuations in 535 lung adenocarcinoma (LUAD), available from The Cancer Genome Atlas (TCGA).